Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques

Circulation

Volumn 108, Issue 6, 2003, Pages 741-747

  Rother, Enno ^a   Brandl, Richard ^b   Baker, Daniel L ^c   Goyal, Pankaj ^a   Gebhard, Harry ^a   Tigyi, Gabor ^c   Siess, Wolfgang ^a,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Apotheke des Klinikums Schwabing   (Germany)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Lipids; Lipoproteins; Plaque; Platelets; Receptors

Indexed keywords

CALCIUM ION; DIOCTYL PHOSPHATIDIC ACID; DIOCTYLGLYCEROL PYROPHOSPHATE; GLYCEROPHOSPHATE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 3; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDIC ACID; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS;

ADENOSINE DIPHOSPHATE; ARTERIOSCLEROSIS; BIOLOGICAL ASSAY; BLOOD PLATELETS; CELL SEPARATION; CELL SIZE; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPINEPHRINE; HUMANS; LIPIDS; LYSOPHOSPHOLIPIDS; MASS SPECTROMETRY; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHATIDIC ACIDS; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 0043020630     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000083715.37658.C4     Document Type: Article

References (34)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Zaman AG, Helft G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000;149:251-266.
3. Weidtmann A, Scheithe R, Hrboticky N, et al. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler Thromb Vasc Biol. 1995;15:1131-1138.
4. Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999;96:6931-6936.
5. Sevanian A, Bittolo BG, Cazzolato G, et al. LDL is a lipid hydroperoxideenriched circulating lipoprotein. J Lipid Res. 1997;38:419-428.
6. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487-1494.
7. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
8. Abi-Younes S, Sauty A, Mach F, et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. 2000;86:131-138.
9. Merten M, Dong JF, Lopez JA, et al. Cholesterol sulfate: a new adhesive molecule for platelets. Circulation. 2001;103:2032-2034.
10. Kamido H, Eguchi H, Ikeda H, et al. Core aldehydes of alkyl glycerophosphocholines in atheroma induce platelet aggregation and inhibit endothelium-dependent arterial relaxation. J Lipid Res. 2002;43:158-166.
11. Hla T, Lee MJ, Ancellin N, at al. Lysophospholipids: receptor revelations. Science. 2001;294:1875-1878.
12. Motohashi K, Shibata S, Ozaki Y, et al. Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett. 2000;468:189-193.
13. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta. 2002;1582:204-215.
14. Tigyi G. Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins Other Lipid Mediat. 2001;64:47-62.
15. Bauer M, Retzer M, Wilde JI, et al. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood. 1999;94:1665-1672.
16. Retzer M, Siess W, Essler M. Mildly oxidised low density lipoprotein induces platelet shape change via Rho-kinase-dependent phosphorylation of myosin light chain and moesin. FEBS Lett. 2000;466:70-74.
17. Retzer M, Essler M. Lysophosphatidic acid-induced platelet shape change proceeds via Rho/Rho kinase-mediated myosin light-chain and moesin phosphorylation. Cell Signal. 2000;12:645-648.
18. Maschberger P, Bauer M, Baumann-Siemons J, et al. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J Biol Chem. 2000;275:19159-19166.
19. 3 inside-out signalling during shape change. Thromb Haemost. 2001;85:331-340.
20. Fischer DJ, Nusser N, Virag T, et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001;60:776-784.
21. Bittman R, Swords B, Liliom K, et al. Inhibitors of lipid phosphatidate receptors: N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids. J Lipid Res. 1996;37:391-398.
22. Kobayashi S, Tokunoh R, Shibasaki M, et al. Synthesis of 1-O-acylglycerol-2, 3-cyclic phosphate: determination of the absolute structure of PHYLPA, a specific inhibitor of DNA polymerase. Tetrahedron Lett. 1993;34:4047-4050.
23. 2+-independent mechanism. J Biol Chem. 1995;270:1057-1061.
24. Mustard JF, Perry DW, Ardlie NG, et al. Preparation of suspensions of washed platelets from humans. Br J Haematol. 1972;22:193-204.
25. Cazenave JP, Mulvihill JN, Sutter-Bay, et al. A Centrifugation Technique for the Preparation of Suspensions of Nonactivated Washed Human Platelets. The Netherlands: Kluwer Academic Publishers; 1993.
26. Brandl R, Richter T, Haug K, et al. Topographic analysis of proliferative activity in carotid endarterectomy specimens by immunocytochemical detection of the cell cycle-related antigen Ki-67. Circulation. 1997;96:3360-3368.
27. Baker DL, Desiderio DM, Miller DD, et al. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem. 2001;292:287-295.
28. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989;69:58-178.
29. Tokumura A, Sinomiya J, Kishimoto S, et al. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem J. 2002;365:617-628.
30. Siess W. Multiple signal-transduction pathways synergize in platelet activation. News Physiol Sci. 1991;6:51-56.
31. Offermanns S. The role of heterotrimeric G proteins in platelet activation. Biol Chem. 2000;381:389-396.
32. 3 activation in platelets. J Biol Chem. 2002;277:39493-39498.
33. Bandoh K, Aoki J, Taira A, et al. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species: structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000;478:159-165.
34. Simon MF, Chap H, Douste-Blazy L. Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: a new group of phospholipid mediators? Biochem Biophys Res Commun. 1982;108:1743-1750.